NewAmsterdam Doses First Patient in Phase 2b SPINOZA Alzheimer's Trial
NAMS is trading near its 52-week low of $21.02 (13% above the low).
Summary
NewAmsterdam Pharma dosed the first patient in SPINOZA, a Phase 2b trial testing obicetrapib in preclinical Alzheimer's disease, expanding the drug's pipeline beyond cardiovascular disease.
Key Events · Product Development and Regulatory · NAMS
-
First Patient Dosed in SPINOZA
The first participant has been dosed in the Phase 2b SPINOZA trial evaluating obicetrapib in preclinical Alzheimer's disease, marking the company's expansion into neurodegenerative indications.
-
Trial Design and Endpoints
SPINOZA will enroll ~400 participants with preclinical Alzheimer's disease, randomized 1:1 to obicetrapib 10 mg or placebo for 52 weeks, with primary endpoint of change in plasma p-tau217 at Week 52.
-
BROADWAY Biomarker Rationale
The trial design was informed by a prespecified BROADWAY Phase 3 analysis showing statistically significant lower p-tau217 changes vs placebo (p=0.025 overall; p=0.022 in ApoE4 carriers), supporting genotype-stratified enrollment.
-
Pipeline Expansion Beyond CVD
SPINOZA adds to obicetrapib's ongoing Phase 3 REMBRANDT, RUBENS, and PREVAIL cardiovascular trials, diversifying the drug's potential indications.
Analysis · NAMS · Life Sciences
Obicetrapib's expansion into Alzheimer's disease marks a meaningful pipeline move beyond the cardiovascular indications that have driven recent regulatory wins in Europe. The first participant has been dosed in the Phase 2b SPINOZA trial, which builds on biomarker data from the Phase 3 BROADWAY study showing statistically significant reductions in p-tau217, a key Alzheimer's pathology marker, particularly in ApoE4 carriers. With ~400 participants and a 52-week treatment period, top-line data is likely more than a year away, but the initiation validates management's thesis that obicetrapib's lipid-modulating mechanism may have neuroprotective effects. For a company with a $2.8B market cap and $678M in cash, this represents a low-cost option on a massive new indication.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAMS was trading at $23.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $21.02 to $42.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.